Using a Recently Approved Tumor Mutational Burden Biomarker to Stratify Patients for Immunotherapy May Introduce a Sex Bias

JCO Precis Oncol. 2021 Nov:5:1147-1150. doi: 10.1200/PO.21.00168.
No abstract available

Publication types

  • Research Support, N.I.H., Intramural

MeSH terms

  • Biomarkers, Tumor / genetics*
  • Female
  • Humans
  • Immune Checkpoint Inhibitors / therapeutic use*
  • Immunotherapy*
  • Male
  • Mutation*
  • Neoplasms / genetics*
  • Neoplasms / therapy*
  • Patient Selection*
  • Sexism*

Substances

  • Biomarkers, Tumor
  • Immune Checkpoint Inhibitors